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INTRODUCTION
Inflammation-mediated endothelial cell damage 
including inflammatory lung vascular injury is often 
associated with caspase activation and endothelial 
cell barrier dysfunction [1]. Over-production of pro-
inflammatory mediators such as tumor necrosis factor 
(TNF)-α is a major cause of endothelial cell injury during 
inflammation [1]. Tumor necrosis factor (TNF)-α-induced 
caspase activation and endothelial cell dysfunction 
contribute to inflammatory vascular injury in endotoxemia 
and sepsis [1]. New agents that can prevent inflammatory 
injury to endothelial cells could provide therapeutic benefits.
Activated caspases are known to induce apoptosis 
by cleaving endogenous substrates and alter other cellular 
functions including cell-cell junctions [2–4]. Caspase-3 
activation plays an important role in endothelial cell 
barrier dysfunction as a result of apoptotic signaling and 
re-organization of cell-cell junction proteins including 
ZO-1 and VE-Cadherin [2–4]. Maintaining of endothelial 
barrier integrity requires interactions of intercellular 
junctions, actin cytoskeleton and microtubules [5]. 
Adherens junctions (AJs) and tight junctions play 
essential roles in supporting endothelial barrier function 
[2–4]. ZO-1 and VE-cadherin are main components of TJs 
and AJs respectively. TNF-α induces endothelial barrier 
disruption by dis-organization of microtubule, actin 
cytoskeleton and cell junctions [6–9].
HDAC6, a member of class II histone deacetylase 
(HDACs) [10–12], is localized in the cytoplasm and 
the nucleus [10–12]. HDAC6 inhibition possesses anti-
tumor and anti-inflammation effects [13–15]. HDAC6 has 
many endogenous substrates including chaperones and 
cytoskeletal proteins [16]. Stabilization of cytoskeletal 
proteins and modulation of chaperones by HDAC6 
may protect against endothelial cell injury [16, 17]. 
Indeed, HDAC6 deletion renders mice less vulnerable to 
endotoxin-induced inflammatory injury [18]. However, the 
effects of HDAC6 inhibition on caspase 3 activation and 
endothelial cell function remain to be determined.
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ABSTRACT
Pro-inflammatory mediators such as TNF-α induce caspase activation in 
endothelial cells, which leads to degradation of cellular proteins, induction of apoptotic 
signaling, and endothelial cell dysfunction. New therapeutic agents that can inhibit 
caspase activation may provide protection against inflammatory injury to endothelial 
cells. In the present study, we examined the effects of selective histone deacetylase 
6 (HDAC6) inhibition on TNF-α induced caspase 3 activation and cell-cell junction 
dysfunction in lung endothelial cells. We also assessed the protective effects of HDAC6 
inhibition against lung inflammatory injury in a mouse model of endotoxemia. We 
demonstrated that selective HDAC6 inhibition or knockdown of HDAC6 expression 
was able to prevent caspase 3 activation in lung endothelial cells and maintain lung 
endothelial cell-cell junctions. Mice pre-treated with HDAC6 inhibitors exhibited 
decreased endotoxin-induced caspase 3 activation and reduced lung vascular injury 
as indicated by the retention of cell-cell junction protein VE-Cadherin level and 
alleviated lung edema. Collectively, our data suggest that HDAC6 inhibition is a potent 
therapeutic strategy against inflammatory injury to endothelial cells.
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Tubastatin A and CAY10603 are potent and highly 
selective HDAC6 inhibitors with IC50 of 15 nM and 2 pM 
in a cell-free assay, respectively [19]. Tubastatin A has been 
reported to possess anti-inflammatory effects [20–23]. 
Tubastatin A treatment can prevent stress responses and 
prolong survival during systemic inflammation [24–28].
In the present study, we investigated the effects of 
HDAC6 knockdown and HDAC6 inhibitors Tubastatin A 
and CAY10603 on TNF-α-induced caspase 3 activation 
in endothelial cells in vitro. We examined the effects of 
Tubastatin A and CAY10603 on cell-cell junction integrity 
and endothelial permeability in primary human lung 
endothelial cells. Furthermore, the effects of Tubastatin A 
and CAY10603 on caspase 3 activation and lung edema 
formation in vivo was assessed in a mouse model of 
endotoxemia. 
RESULTS
Tubstatin a inhibits TNFα-induced caspase-3 
activation in lung endothelial cells
TNF-α is a major pro-inflammatory mediator 
known to induce endothelial injury during inflammation 
(17, 21, 27).  TNF-α induces caspase 3 activation which 
leads to subsequent cellular damage including endothelial 
barrier dysfunction [29, 30]. We first assessed whether 
HDAC6 inhibition can block caspase-3 activation in lung 
endothelial cells. HPAECs and HLMVECs were pre-
treated with Tubstatin A, then challenged with TNF-α. Our 
results showed that Tubstatin A potently blocked TNF-α-
induced caspase-3 activation (cleaved caspase-3 level) in 
endothelial cells (Figure 1). 
HDAC6 knockdown and CAY10603 treatment 
attenuate TNF-α-induced caspase-3 activation in 
endothelial cells
To confirm the specific effects of HDAC6 inhibition 
on TNF-α-induced caspase-3 activation, we used HDAC6 
siRNA knockdown and another selective HDAC6 inhibitor 
CAY10603 in our study. HPAECs were challenged with 
TNF-α after siRNA knockdown or CAY10603 treatment. 
HDAC6 knockdown and CAY10603 treatment both 
inhibited TNF-α-induced caspase-3 activation (Figure 2). 
HDAC6 inhibition alleviates TNF-α-induced 
disruption of tight junctions in endothelial cells
Caspase-3 activation is associated with endothelial 
cell-cell junction disruption [2–4]. We next conduct 
experiments to assess whether HDAC6 inhibition could 
Figure 1: HDAC6 inhibition by Tubastatin A attenuates caspase-3 activation in endothelial cells. HPAECs and HLMVECs 
were pre-treated with Tubastatin A (TubA, 3 µM) for 6 h, then challenged with TNF-α (20 ng/ml) for 18 h. Cells were divided into 4 groups: 
Control (Con), TNF-α alone (TNFα), Tubastatin A alone (TubA), and TNF-α+Tubastatin A (TNFα+TubA). Representative blots and 
densitometry analysis of cleaved-caspase-3 in HPAECs (A) and HLMVECs (B). *P < 0.05 versus TNF-α group, n = 3.
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prevent TNF-α-induced damage to endothelial cell-
cell junctions. We observed endothelial cells ZO-1 
disassembly at tight junctions after TNF-α challenged by 
immunofluorescence assay. Pre-treatment with Tubstatin 
A prevented the disruption in HPAECs and HLMVECs 
(Figure 3).  
HDAC6 inhibition blocks endotoxin-induced 
caspase-3 activation and VE-Cadherin down-
regulation in the lung
To assess the therapeutic potential of HDAC6 
inhibition against endothelial cell injury during acute 
inflammation, we examined the effects of CAY10603 on 
caspase-3 activation in a mouse model of endotoxemia. 
In our studies, endotoxin-induced caspase-3 activation in 
the lung tissues was significantly inhibited by CAY10603 
and Tubastatin A pre-treatment. (Figure 4). Furthermore, 
endotoxin challenge caused down-regulation of adherens 
junction protein VE-Cadherin in the lung tissues. The 
down-regulation of VE-Cadherin was also blocked by 
CAY10603 and Tubastatin A pre-treatment (Figure 5).
HDAC6 inhibition reduces TNF-α-induced 
endothelial permeability and attenuates lung 
edema formation in endotoxemia
TNF-α is a major pro-inflammatory mediator known 
to induce trans-endothelial hyper-permeability during 
inflammation [1, 7, 9]. We examined the effects of HDAC6 
inhibition by CAY10603 on TNF-α-induced endothelial 
permeability. TNF-α challenge caused increased 
endothelial permeability to FITC-dextran in HPAECs. 
Cells pre-treated with CAY10603 exhibited significant 
reduction of TNF-α-induced endothelial permeability to 
FITC-dextran (Figure 6A). We also examined the effects 
of CAY10603 on lung vascular permeability in the mouse 
model of endotoxemia. In our studies, endotoxin-induced 
lung edema formation was significantly inhibited by 
CAY10603 pre-treatment (Figure 6B).
Figure 2: HDAC6 knockdown and HDAC6 inhibition by CAY10603 block TNF-α-induced caspase-3 activation in 
endothelial cells. (A)  HPAECs were transfected with HDAC6 siRNA or control siRNA for 48 h, then challenged with TNF-α (20 ng/ml) 
for 24 h. Cells were divided into 4 groups: Control (Con), TNF-α alone (TNFα), siRNA alone (siRNA), and TNF-α+siRNA(TNFα+siRNA). 
(B) HPAECs were pre-treated with CAY10603 (CAY, 0.1 µM) for 6 h, then challenged with TNFα (20 ng/ml) for 18 h. Cells were divided 
into 4 groups: Control (Con), TNF-α alone (TNFα), CAY10603 alone (CAY), and TNF-α+CAY10603 (TNFα+CAY). Representative blots 
and densitometry analysis of cleaved caspase-3. *P < 0.05 versus TNF-α group, n = 3.
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Figure 3: HDAC6 inhibition prevents TNF-α-induced ZO-1 disassembly in endothelial cells. HPAECs and HLMVECs were 
pre-treated with Tubastatin A (TubA, 3 µM) for 6 h, then challenged with TNF-α (20 ng/ml) for 18 h. Cells were divided into 4 groups: 
Control (Con), TNF-α alone (TNFα), Tubastatin A alone (TubA), and TNF-α+Tubastatin A (TNFα+TubA). Immunofluorescence staining 
of ZO-1 in HPAECs (A) and HLMVECs (B). Images are representatives of three to six independent experiments.
Figure 4: HDAC6 inhibition reduced LPS-induced lung caspase-3 activation in endotoxemia. (A) C57BL/6 mice were 
divided into four groups: Control (Con, n = 6); LPS (LPS, n = 7), CAY10603 (CAY, n = 6); CAY10603+LPS (CAY+LPS, n = 7). Mice 
were pre-treated with CAY10603 for 2 h, then challenged with LPS for 24 h. Lung tissue were collected. (B) C57/B6 mice were divided 
into three groups: Control (Con, n = 6); LPS (n = 7); Tubastatin A (TubA) + LPS (n = 6). Mice were pre-treated with Tubastatin A for 6 h, 
then challenged with LPS. 24 h after LPS challenge, lung tissues were collected. Representative blots and densitometry analysis of cleaved 
caspase-3 in lung tissues.  *P < 0.05 versus LPS group.
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Figure 5: HDAC6 inhibition prevents LPS-induced VE-cadherin down-regulation in lung tissues. (A) C57BL/6 mice were 
divided into four groups: Control (Con, n = 6); LPS (LPS, n = 7), CAY10603 (CAY, n = 6); CAY10603+LPS (CAY+LPS, n = 7). Mice were 
challenged by CAY10603 for 2 h, then challenged with LPS for 24 h. Lung tissue were collected. (B) C57BL/6 mice were divided into three 
groups: Control (Con, n = 6); LPS (n = 7); Tubastatin A (TubA)+LPS (n = 6). Mice were challenged by LPS with or without Tubastatin A 
(TubA) pre-treatment. 24 h after LPS challenge, lung tissues were collected. Representative blots and densitometry analysis of VE-cadherin 
level in lung tissues. *P < 0.05 versus LPS group. 
Figure 6: HDAC6 inhibition alleviates TNF-α-induced endothelial hyper-permeability and lung edema in endotoxemia. 
(A) HPAECs were pre-treated with CAY10603 (CAY, 0.1 µM) for 6 h, then challenged with TNFα (20 ng/ml) for 18 h. Cells were divided 
into 4 groups: Control (Con), TNF-α alone (TNFα), CAY10603 alone (CAY), and TNF-α+CAY10603 (TNFα+CAY). TNF-α-induced 
endothelial permeability to FITC-Dextran was measured (n = 4). *P < 0.05 versus TNF-α group. (B) C57BL/6 mice were divided into four 
groups: Control (Con, n = 6); LPS (LPS, n = 7), CAY10603 (CAY, n = 6); CAY10603+LPS (CAY+LPS, n = 7). Mice were pre-treated with 
CAY10603 for 2 h, then challenged with LPS for 24 h. Lung Wet/Dry weight ratio was measured. *P < 0.05 versus LPS group.
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DISCUSSION
TNF-α is a potent pro-inflammatory mediator known 
to cause endothelial cell apoptosis and endothelial barrier 
disruption [7, 9, 31–33]. TNF-α plays an important role 
in many inflammatory diseases including lung vascular 
injury [1]. Activation of caspases including caspase 3 
contributes to TNF-α induces endothelial cell dysfunction 
such as hyper-permeability [2–4].  Caspase activation 
mediates apoptotic signaling and disruption of cell 
junction complex [2–4], contributing to TNF-α-induced 
breakdown of endothelial barrier function [2–4]. Similar 
effects were observed in our in vitro studies in primary 
human lung endothelial cells. Therefore, new agents that 
can inhibit TNF-α-induced caspase activation and preserve 
endothelial cell junctions could serve as therapeutic agents 
against TNF-α-induced endothelial cell dysfunction.
HDAC6 inhibition has been reported to prolong 
survival in murine models of systemic inflammation and 
injury [20, 24, 25]. However, mechanisms underlying the 
protective effects observed by HDAC6 inhibition remain 
to be determined. In the present study, we demonstrated 
that HDAC6 inhibition potently inhibited TNF-α-induced 
caspase 3 activation and endothelial barrier dysfunction, 
suggesting that HDAC6 inhibition could provide protection 
against inflammation-mediated endothelial cell injury.
Caspase activation mediates apoptosis and re-
distribution of proteins that are known to modulate 
endothelial barrier function including ZO-1 and VE-
Cadherin [2–4]. Protein acetylation can modulate caspase 
activation [2]. In our studies, HDAC6 inhibition by 
HDAC6 inhibitors or siRNA knockdown resulted in 
reduced caspase 3 activation. It has been reported that 
microtubule disruption leads to increased apoptotic 
signaling and caspase activation [34, 35]. α-tubulin is 
a endogenous substrate of HDAC6 [10, 11, 36–38]. 
Acetylation of α-tubulin at Lys40 stabilizes microtubule 
structures [12, 38–41].  The decreased caspase 3 activation 
by HDAC6 inhibition could be due to its protection 
against microtubule disassembly by α-tubulin acetylation. 
HDAC6 has been reported to modulate the function of 
chaperones such as Hsp90 [17]. Inhibition of HDAC6 
down-regulates Hsp90-dependent RhoA activity and 
signaling, which then suppresses actin cytoskeleton re-
organization and cell contraction [17]. HDAC6 has also 
been reported to modulate the function of Survivin, an 
anti-apoptotic protein [42].  Survivin inhibits apoptotic 
signaling by inactivating caspases [42].  Our data suggest 
that inhibition of caspase-3 activation by HDAC6 
inhibition provides potent protection against TNF-α-
induced endothelial cell dysfunction.
We also showed that HDAC6 inhibition effectively 
suppress caspase-3 activation and maintain lung endothelial 
barrier integrity in vivo. HDAC6 inhibitors prevented 
caspase 3 activation in lung tissues with reduced lung 
edema in a mouse model of endotoxemia. Maintaining VE-
Cadherin expression is critical in supporting lung vascular 
barrier integrity [43]. We demonstrated that Tubastatin A 
and CAY10603 were able to prevent the reduction of VE-
Cadherin in lung tissues after LPS challenge. Our results 
suggest that HDAC6 inhibition is a new approach that can 
modulate endothelial cell junction stability in inflammatory 
lung injury. More studies are needed in the future to further 
investigate this new pathway.
In summary, selective HDAC6 inhibition by 
CAY10603 and Tubastatin A prevents TNF-α-induced 
endothelial cell dysfunction. HDAC6 inhibitors prevent 
caspase-3 activation in endothelial cells and inhibit TNF-
α-induced endothelial barrier dysfunction by maintaining 
cell-cell junction integrity.  HDAC6 inhibitors prevented 
endotoxin-induced lung caspase-3 activation and lung 
edema, suggesting that selective HDAC6 inhibition 
possesses therapeutic potential to treat endothelial cell 
dysfunction during acute inflammation.
MATERIALS AND METHODS
Reagents
β-actin, ZO-1, caspase-3 antibodies were 
purchased from Cell Signaling Technology (Danvers, 
Massachusetts). VE-cadherin antibody was obtained from 
Santa Cruz Biotechnology (Dallas, Texas). Recombinant 
Human TNF-α was from R&D Systems (Minneapolis, 
Minnesota). Tubastatin A, CAY10603 were obtained from 
Selleck Chemicals (Houston, Teaxs). Lipopolysaccharide 
(LPS) from Escherichia coli 0111:B4 was purchased from 
Sigma Aldrich (St. Louis, Missouri). Endothelial growth 
medium (EBM-2) was obtained from Lonza (Allendale, 
NJ).  In Vitro Vascular Permeability Assay (96-Well) 
kit was purchased from EMD Millipore (Billerica, 
Massachusetts). Lipofectamine RNAiMAX reagent, 
HDAC6 siRNA and control siRNA were obtained from 
Life technologies (Carlsbad, California).
Cell culture      
Human pulmonary arterial endothelial cells 
(HPAECs) and human lung microvascular endothelial 
cells (HLMVECs) were purchased from Lonza (Allendale, 
NJ). Cells were grown in EGM-2 supplemented with fetal 
bovine serum (FBS) and cultured in an incubator at 37°C 
in 5% CO2 and 95% air. Cells from passages 5 to 9 were 
used in the experiments.
HDAC6 siRNA knockdown 
HDAC6 siRNA knockdown was conducted as 
described previously [41]. Cells were transfected with 
siRNAs for 48 h according to the manufacture’s protocol. 
siRNA-transfected cells were then stimulated with 20 ng/ml 
TNF-α for 24 h. 
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Immunofluorescence and immunoblotting assays
For immunofluorescence assay, cells were grown 
on glass coverslips pre-coated with 0.1% gelation. After 
the treatment, cells were fixed in –20°C methanol and 
washed with PBS on ice.  Cells were blocked with 1% 
BSA in PBS, then incubated with primary antibody. After 
3 washes with TBS, cells were incubated with Alexa Fluor 
594 secondary antibody. The coverslips were mounted 
on the slides with DAPI. Immunoblotting assays of cell 
and lung tissue samples were conducted as described 
previously [43, 44].
Mouse model of endotoxemia 
Eleven to twelve week-old male C57BL/6 mice were 
purchased from Jackson Lab. All experiments and animal 
care procedures were approved by the Institutional Animal 
Care and Use Committee of the University of Kentucky. 
Endotoxemia was induced by I.P. injection of 7.5 mg/kg 
LPS in phosphate buffered saline (PBS). Mice were 
pre-treated by I.P. injection with Tubstatin A (9 mg/kg 
body weight) for 6 h or CAY10603 (5 mg/kg body 
weight) for 2 h before LPS challenge. Experiments were 
terminated 24 h after LPS challenge. Lung wet/dry weight 
ratio was assessed as described previously [43]. 
Endothelial cell permeability assay
In Vitro Vascular Permeability Assay (96-Well) 
kit was used to measure endothelial cell monolayer 
permeability to FITC-dextran according to the 
manufacture’s protocol. Briefly, endothelial cells were 
seeded into the insert. 72 h later, endothelial cells formed 
a monolayer. Endothelial cell monolayers were pre-
treated with CAY10603 (CAY, 0.1 µM) for 6 h, and 
then stimulated with TNF-α for 18 h.  A high molecular 
weight (2000 kD) FITC-Dextran was diluted in EGM-2 
medium (1:40) and added into the insert. 20 minutes after 
the incubation, 100 µl medium from lower chamber was 
collected. Fluorescence intensity was measured in a plate 
with a fluorescence plate reader.
Statistical analysis
Results are expressed as means ± SE of 3 to 6 
independent experiments. ANOVA and post hoc multiple 
comparison tests were used for multiple groups. The 
Student′s t-test was used for comparisons of two groups. 
Statistical significance was assigned to P values < 0.05.
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